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Abstract
Background: Interleukin-17 (IL-17) cytokines and receptors play an important role in many
autoimmune and inflammatory diseases. IL-17 receptors IL-17RA and IL-17RC have been found to
form a heterodimer for mediating the signals of IL-17A and IL-17F cytokines. While the function
and signaling pathway of IL-17RA has been revealed, IL-17RC has not been well characterized. The
function and signaling pathway of IL-17RC remain largely unknown. The purpose of the present
study was to systematically examine IL-17RC protein expression in 53 human tissues.
Results:  IL-17RC expression in 51 normal human tissues and two benign tumors (i.e.,
lymphangioma and parathyroid adenoma) on the tissue microarrays was determined by
immunohistochemical staining, using two polyclonal antibodies against IL-17RC. IL-17RC protein
was expressed in many cell types including the myocardial cells, vascular and lymphatic endothelial
cells, glandular cells (of the adrenal, parathyroid, pituitary, thyroid, pancreas, parotid salivary, and
subepidermal glands), epithelial cells (of the esophagus, stomach, intestine, anus, renal tubule,
breast, cervix, Fallopian tube, epididymis, seminal vesicle, prostate, gallbladder, bronchus, lung, and
skin), oocytes in the ovary, Sertoli cells in the testis, motor neurons in the spinal cord, autonomic
ganglia and nerves in the intestine, skeletal muscle cells, adipocytes, articular chondrocytes, and
synovial cells. High levels of IL-17RC protein expression were observed in most vascular and
lymphatic endothelium and squamous epithelium. The epithelium of the breast, cervix, Fallopian
tube, kidney, bladder and bronchus also expressed high levels of IL-17RC, so did the glandular cells
in the adrenal cortex, parotid salivary and subepidermal glands. In contrast, IL-17RC protein was
not detectable in the smooth muscle cells, fibroblasts, antral mucosa of the stomach, mucosa of the
colon, endometrium of the uterus, neurons of the brain, hepatocytes, or lymphocytes.
Nevertheless, IL-17RC protein was expressed in the vascular endothelium within the tissues where
the IL-17RC-negative cells resided.
Conclusion: IL-17RC protein is expressed in most human tissues, the function of which warrants
further investigation.
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Background
Interleukin-17 (IL-17) family has six cytokines, i.e., IL-
17A (or IL-17), IL-17B, IL-17C, IL-17D, IL-17E, and IL-
17F [1,2]. IL-17A/F heterodimer has also been reported
[3,4]. There are five receptors: IL-17RA (or IL-17R), IL-
17RB (or IL-17Rh1), IL-17RC (or IL-17RL), IL-17RD, and
IL-17RE. IL-17RA is the receptor for IL-17A and IL-17F
[5,6]. IL-17RB is the receptor for IL-17B and IL-17E [7,8].
IL-17RD binds to fibroblast growth factor (FGF) receptor
and inhibits the FGF receptor-mediated extracellular sig-
nal-regulated kinase (ERK) pathway [9-12]. The receptors
for IL-17C and IL-17D cytokines have not been identified,
nor the cytokines for IL-17RD and IL-17RE. In general, the
IL-17 family plays proinflammatory functions [2,13-15].
IL-17A and IL-17F are secreted by a subtype of CD4+ T
cells, which are named T helper 17 (TH17) [16,17]. IL-17A
is also produced by some CD8+ T cells and the T cells
expressing αβ or γδ T cell receptor [18-20]. IL-17A and IL-
17F contribute to a number of autoimmune and inflam-
matory diseases such as rheumatoid arthritis [21,22],
inflammatory bowel diseases [23,24], multiple sclerosis
[17,25,26], organ allograft rejection [27,28], psoriasis
[29,30], airway inflammation [31,32], and tumor growth
[33,34].
The IL-17RC gene located on 3p25.3 has 19 exons. With
22% identity to IL-17RA, the full-length IL-17RC protein
is a 720-amino acid type I transmembrane protein with a
20-amino acid signal peptide, a 447-amino acid N-termi-
nal extracellular domain, a 21-amino acid hydrophobic α-
helical transmembrane domain, and a 232-amino acid
intracellular domain. IL-17RC mRNAs are detected in
human prostate, kidney, cartilage, liver, heart, skeletal
muscle, and at lower levels in the intestines, brain, lung
and spleen [35]. IL-17RC expression was also found in
human umbilical vein endothelial cells and chondrocytes
and mouse cardiac fibroblasts [36-38]. There are at least
13 mRNA splice isoforms including the full-length and
exon(s)-deleted isoforms [39]. The significance of splice
variation is unknown. It has been shown that the full-
length IL-17RC formed homodimer and inhibited TNFα-
induced apoptosis in prostate cancer cells [40].
Homodimerization of IL-17RA has also been reported
[41]. IL-17RC forms heterodimers with IL-17RA to medi-
ate IL-17A and IL-17F signals in mouse stromal cells [42]
and human gastric adenocarcinoma AGS cells and synovi-
ocytes [43,44]. Recently, it has been shown that IL-17RC
functions as a receptor for both IL-17A and IL-17F [45].
Deletion of exon 7 of human IL-17RC does not affect its
binding to human IL-17A and IL-17F, but deletion of
exon 12 does abolish ligand binding capacity [45]. Inter-
estingly, mouse IL-17A does not bind to any forms of
human or mouse IL-17RC, whereas mouse IL-17F only
binds to the full-length human and mouse IL-17RC but
not to exon-deleted isoforms [45].
We have recently reported that different IL-17RC protein
forms were differentially expressed in the immortalized
normal prostatic epithelium and prostate cancer cells
[46]. Here we report the results of immunohistochemical
staining for IL-17RC protein expression in over 50 human
normal tissues.
Results and discussion
In this study, we examined IL-17RC expression in 51 nor-
mal human tissues and two benign tumors (i.e., lym-
phangioma and parathyroid adenoma, due to the
difficulties in sampling these normal tissues according to
the tissue microarray provider) by immunohistochemical
staining, using two different polyclonal antibodies against
IL-17RC that have been characterized previously
[35,39,40,46,47]. The rabbit anti-IL-17RC intracellular
domain antibodies (anti-ICD) that recognize an intracel-
lular domain (peptide sequence: DSYFHPPGTPAPGR) of
IL-17RC protein were affinity-purified [35]. The goat anti-
IL-17RC extracellular domain antibodies (anti-ECD) were
generated using the extracellular domain of human IL-
17RC isoform #3 (in which exon 7 was spliced out) as
immunogen. Therefore, it is possible that the anti-ECD
antibodies may recognize a soluble receptor that contains
only the extracellular domain, whereas this soluble recep-
tor can not be recognized by the anti-ICD antibodies. Pre-
viously, we have reported that the IL-17RC protein
recognized by the anti-ECD antibodies was highly
expressed in the normal prostatic epithelium, but signifi-
cantly decreased or was absent in the prostate cancer cells
[46]. In contrast, the IL-17RC protein recognized by the
anti-ICD antibodies was expressed at higher levels in the
prostate cancer cells than in the normal prostatic epithe-
lium [46]. Both antibodies recognized the same recom-
binant full-length IL-17RC expressed in 293 cells,
although the anti-ECD antibodies had lower affinity than
the anti-ICD antibodies in the Western blot analysis. Nev-
ertheless, both antibodies detected similar levels of IL-
17RC protein expression in vascular endothelium by
immunohistochemical staining [46]. The results of the
current study were summarized in Table 1 and described
below.
Cardiovascular system
The smooth muscle cells in the aorta did not express any
IL-17RC as detected by either the anti-ICD or anti-ECD
antibodies (Figure 1,A and 1,A'). The myocardial cells had
weak staining of IL-17RC by both antibodies, whereas the
cardiac vascular endothelium had intermediate to strong
IL-17RC staining (Figure 1,B and 1,B'). The lymphatic
endothelium in a lymphangioma was stained weakly by
the anti-ICD antibodies but strongly by the anti-ECD anti-
bodies (Figure 1,C and 1,C'). The endothelium of the
small arteries or arterioles in the lung was stained strongly
by both the anti-ICD and anti-ECD antibodies (Figure 1,DInternational Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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Table 1: Expression of IL-17RC protein in human tissues.
Figure number Age of donor Organ/tissue Cell type Anti-ICD Anti-ECD
1A/A' 27 Aorta Smooth muscle - -
1B/B' 59 Heart Myocardium + +
1C/C' 27 Lymphangioma Lymphatic endothelium + +++
1D/D' 56 Lung Small artery, endothelium +++ +++
1E/E' 49 Intestine Small vein, endothelium +++ ++
2A/A' Unknown Adrenal gland Cortex, glandular cell +++ ++
2B/B' Unknown Adrenal gland Medulla, glandular cell + +
2C/C' 59 Parathyroid Adenoma, glandular cell - ++
2D/D' 78 Pituitary Anterior, glandular cell + ++
2E/E' 48 Thyroid gland Glandular cell + +
3A/A' 81 Esophagus Squamous cell - +++
3B/B' 43 Stomach Antral mucosa, epithelium - -
3C/C' 53 Stomach Oxyntic mucosa, epithelium + ++
3D/D' 45 Small intestine Mucosa, epithelium - +
3E/E' 59 Colon Mucosa, epithelium - -
3F/F' 59 Anus Mucosa, squamous cell - +++
4A/A' 46 Breast Gland, epithelium - +++
4B/B' 55 Cervix Ectocervix, squamous cell - +++
4C/C' 60 Cervix Endocervix, epithelium - ++
4D/D' 49 Uterus Endometrium, secretory - -
4E/E' 52 Fallopian tube epithelium - +++
4F/F' 18 Ovary oocyte + +
5A/A' 72 Testis Seminiferous tubule ++ +
5B/B' 83 Epididymis epithelium ++ ++
5C/C' 56 Seminal vesicle epithelium + +
5D/D' 41 Prostate epithelium - +++
6A/A' 78 Brain Cerebral cortex, neuron - -
6B/B' 78 Brain Cerebellar cortex, purkinje/granular cell - -
6C/C' 78 Brain Ependymal cell - -
6D/D' 78 Hippocampus Neuron - -
6E/E' 78 Spinal cord Motor neuron + +
6F/F' 52 Intestine Autonomic ganglia + +
7A/A' 58 Liver Hepatocyte - -
7B/B' 69 Gallbladder Epithelium + ++
7C/C' 43 Pancreas Glandular cell - ++
7D/D' 65 Salivary gland, parotid Glandular cell +++ +++
8A/A' 62 Kidney Cortex, glomerulus +++ +++
8B/B' 91 Kidney Medulla, epithelium + +++
8C/C' 41 Bladder Transitional epithelium + +++
8D/D' 73 Lung Alveoli, epithelium + ++
8E/E' 73 Bronchus Epithelium - +++
9A/A' 60 Skin Squamous cell - ++
9B/B' 60 Subepidermis Glandular cell + +++
9C/C' 76 Lymph node Lymphatic cell - -
9D/D' 52 Spleen Lymphatic cell - -
9E/E' 32 Thymus Lymphatic cell - -
9F/F' 4 Tonsil Lymphatic cell - -
10A/A' 49 Skeletal muscle Skeletal muscle cell - +
10B/B' 52 Instestine Smooth muscle cell - -
10C/C' 55 Uterus Smooth muscle cell - -
10D/D' 39 Breast Adipocyte + +
10E/E' 62 Cartilage, articular Chondrocyte + -
10F/F' 62 Synovium Synovial cell ++ -
The intensity of IL-17RC staining for a particular cell type in the tissues was graded in this way: - = no staining; + = weak; ++ = intermediate; +++ = 
strong. The vascular endothelium had intermediate to strong staining in most tissues.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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IL-17RC expression in the cardiovascular system Figure 1
IL-17RC expression in the cardiovascular system. Arrows: endothelium. Original magnification: × 400. Figure D, D', E, 
and E' were reproduced from a previous publication in Neoplasia, 9 (6): 464–470, 2007, with permission by Neoplasia Press 
and the author Z. You.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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and 1,D'). The endothelium of the small veins in the
intestine was stained strongly by the anti-ICD anti-bodies
and intermediately by the anti-ECD antibodies (Figure 1,E
and 1,E'). A previous study suggested that the anti-ICD
and anti-ECD antibodies recognize different IL-17RC pro-
tein forms [46]. The current results indicate that these dif-
ferent IL-17RC proteins are expressed at similar levels in
the vascular and lymphatic endothelium. It has been
reported that a combination of hepatocyte growth factor
(HGF) and vascular endothelial cell growth factor (VEGF)
markedly induced a number of chemokine and cytokines
and their receptors (IL-8, IL-6, IL-11, CCR6, CXCR1,
CXC1, and IL-17RC) in human umbilical vein endothelial
cells [37]. It is unknown what role IL-17RC plays in the
endothelium under inflammation.
Endocrine system
The glandular cells in the adrenal cortex were stained
strongly and intermediately by the anti-ICD and anti-ECD
antibodies, respectively (Figure 2,A and 2,A'), whereas the
glandular cells in the adrenal medulla were stained weakly
by both antibodies (Figure 2,B and 2,B'). Interestingly, the
vascular endothelium was not stained by the anti-ICD
antibodies but stained strongly by the anti-ECD antibod-
ies in both the adrenal cortex and medulla (Figure 2,A/A'
and 2B/B'). In a parathyroid adenoma tissue, the glandu-
lar cells were not stained by the anti-ICD antibodies but
stained intermediately by the anti-ECD antibodies, while
the vascular endothelium was not stained by either anti-
bodies (Figure 1,C and 1,C'). The glandular cells of the
anterior pituitary gland were stained weakly and interme-
diately by the anti-ICD and anti-ECD antibodies, respec-
tively, while the vascular endothelium was stained
intermediately only by the anti-ECD antibodies (Figure
2,D and 2,D'). The glandular cells of the thyroid gland
were stained weakly by both antibodies (Figure 2,E and
2,E'). The function of IL-17RC in the endocrine glands is
not known.
Gastrointestinal tract
The esophageal squamous mucosa was not stained by the
anti-ICD antibodies but stained strongly by the anti-ECD
antibodies, although the vascular endothelium was
stained strongly by both antibodies (Figure 3,A and 3,A').
The antral mucosa of the stomach was not stained by
either antibodies (Figure 3,B and 3,B'), whereas the oxyn-
tic mucosa was stained weakly and intermediately by the
anti-ICD and anti-ECD antibodies, respectively (Figure
3,C and 3,C'). The mucosa of the small intestine was not
stained by the anti-ICD antibodies, but stained weakly by
the anti-ECD antibodies (Figure 3,D and 3,D'). Interest-
ingly, the goblet cells were stained strongly by the anti-
ECD antibodies but not stained by the anti-ICD antibod-
ies (Figure 3,D and 3,D'). The mucosa of the colon was
not stained by either antibodies, although the vascular
endothelium in the background was stained positively
(Figure 3,E and 3,E'). Like in the esophagus, the squamous
mucosa of the anus was not stained by the anti-ICD anti-
bodies but stained strongly by the anti-ECD antibodies,
although the vascular endothelium was stained positively
by both antibodies (Figure 3,F and 3,F'). The significance
of differential expression of different IL-17RC proteins in
the esophagus and anus is yet to be determined. Given the
purported role of IL-17 cytokines in inflammatory bowel
diseases [23,24], the absence of IL-17RC in the colon epi-
thelium and its presence in the vascular endothelium sug-
gest that the IL-17 cytokines may act on the vascular
epithelium in the lesion to contribute to the local inflam-
mation.
Breast and female reproductive system
The glandular epithelium of female breast was not stained
by the anti-ICD antibodies but stained strongly by the
anti-ECD antibodies, although the vascular endothelium
was stained strongly by both antibodies (Figure 4,A and
4,A'). It remains to be tested if breast cancer expresses
higher levels of IL-17RC that is recognized by the anti-ICD
antibodies, as this trend was observed in the prostate [46].
The squamous mucosa of the ectocervix was not stained
by the anti-ICD antibodies but stained strongly by the
anti-ECD antibodies (Figure 4,B and 4,B'). Similarly, the
epithelium of the endocervix was not stained by the anti-
ICD antibodies but stained intermediately by the anti-
ECD antibodies (Figure 4,C and 4,C'). The secretory
endometrium of uterus was not stained by either antibod-
ies (Figure 4,D and 4,D'). In the Fallopian tube, the epi-
thelium was not stained by the anti-ICD antibodies but
stained strongly by the anti-ECD antibodies (Figure 4,E
and 4,E'). The oocytes in the ovary were stained weakly by
both antibodies (Figure 4,F and 4,F'). The function of IL-
17RC in these tissues is not known.
Male reproductive system
In the seminiferous tubule of the testis, the Sertoli cells
were stained intermediately and weakly by the anti-ICD
and anti-ECD antibodies, respectively, whereas the sper-
matogonia and spermatocytes were not stained by either
antibodies (Figure 5,A and 5,A'). The epithelium of the
epididymis and seminal vesicle were stained intermedi-
ately and weakly by both antibodies, respectively (Figure
5,B,B' and 5C,C'). In the prostate, the epithelium was not
stained by the anti-ICD antibodies but stained strongly by
the anti-ECD antibodies (Figure 5,D and 5,D'). We have
previously demonstrated that the IL-17RC protein recog-
nized by the anti-ICD antibodies was increased in the
prostate cancer cells, whereas the IL-17RC protein recog-
nized by the anti-ECD antibodies was decreased in the
prostate cancer cells [46]. We speculate that expression of
different IL-17RC proteins may be related to the respon-
siveness of the epithelial cells to the IL-17 cytokines,International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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IL-17RC expression in the endocrine system Figure 2
IL-17RC expression in the endocrine system. Arrows: endothelium; and open arrow: glandular cells. Original magnifica-
tion: × 400.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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IL-17RC expression in the gastrointestinal tract Figure 3
IL-17RC expression in the gastrointestinal tract. Arrows: endothelium; open arrows: squamous epithelium (A, A', F, and 
F') and epithelium (B, B', C, C', D, D', E, and E'); and asterisks: goblet cells (D and D'). Original magnification: × 400.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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IL-17RC expression in the breast and female reproductive system Figure 4
IL-17RC expression in the breast and female reproductive system. Arrows: endothelium; open arrows: epithelium 
(A, A', C, C', D, D', E, and E'), squamous epithelium (B and B'); and oocytes (F and F'). Original magnification: × 400. Figure A 
and A' were reproduced from a previous publication in Neoplasia, 9 (6): 464–470, 2007, with permission by Neoplasia Press 
and the author Z. You.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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IL-17RC expression in the male reproductive system Figure 5
IL-17RC expression in the male reproductive system. Arrows: Sertoli cells (A and A') and epithelium (B, B', C, C', D, 
and D'); and open arrows: spermatogonia (A and A'). Original magnification: × 400. Figure D and D' were reproduced from a 
previous publication in Neoplasia, 9 (6): 464–470, 2007, with permission by Neoplasia Press and the author Z. You.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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which needs to be investigated. The function of IL-17RC
in the testis, epididymis and seminal vesicle is not known.
Nervous system
The neurons in the cerebral and cerebellar cortices were
not stained by either the anti-ICD or anti-ECD antibodies
(Figure 6,A/A' and 6B/B'). Neither the ependymal cells
nor the neurons in the hippocampus were stained by
either antibodies (Figure 6,C/C' and 6D/D'). Of note, the
vascular endothelium in the aforementioned tissues was
not stained by the anti-ICD antibodies but stained
strongly by the anti-ECD antibodies. It has been demon-
strated that IL-17A plays an important role in the experi-
mental autoimmune encephalomyelitis [26,48-57]. Yet, it
is not clear whether IL-17RC in the vascular endothelium
of the brain plays any role in this autoimmune disease.
Interestingly, the motor neurons in the spinal cord and
the intestinal autonomic ganglia were stained weakly by
both antibodies (Figure 6,E/E' and 6F/F').
Liver, gallbladder, pancreas, and salivary gland
The hepatocytes were not stained by either the anti-ICD or
anti-ECD antibodies, although the sinusoid endothelium
was stained intermediately by the anti-ECD but not the
anti-ICD antibodies (Figure 7,A and 7,A'). The gallbladder
epithelium was stained weakly and intermediately by the
anti-ICD and anti-ECD antibodies, respectively (Figure
7,B and 7,B'). The glandular cells of the pancreas were not
stained by the anti-ICD antibodies, whereas they were
stained intermediately by the anti-ECD antibodies (Figure
7,C and 7,C'). It has been reported that IL-17A in combi-
nation with IL-1 and TNFα induced IL-6 secretion by the
pancreatic periacinar myofibroblasts, which might play
an important role in the pathophysiology of acute pancre-
atitis [58]. Whether the pancreatic glandular cells respond
to IL-17A is yet to be determined. Interestingly, the glan-
dular cells of the parotid salivary gland were stained
strongly by both antibodies (Figure 7,D and 7,D').
Urinary and respiratory systems
The glomerulus of the renal cortex was stained strongly by
both the anti-ICD and anti-ECD antibodies (Figure 8,A
and 8,A'), due possibly to the vascular nature of the
glomerular tufts. In the renal medulla, the tubular epithe-
lium was stained weakly and strongly by the anti-ICD and
anti-ECD antibodies, respectively (Figure 8,B and 8,B').
Similarly, the transitional epithelium of the bladder was
stained weakly and strongly by the anti-ICD and anti-ECD
antibodies, respectively (Figure 8,C and 8,C'). In the lung,
the alveolar lining cells and the capillary endothelial cells
were stained weakly and intermediately by the anti-ICD
and anti-ECD antibodies, respectively (Figure 8,D and
8,D'). However, the bronchial epithelium was not stained
by the anti-ICD antibodies but stained strongly by the
anti-ECD antibodies (Figure 8,E and 8,E'). IL-17A and IL-
17F have been shown to play an important role in airway
inflammation [31,32,57]. IL-17RA is localized to basal
airway cells in human lung tissue and functional IL-17RA
signaling occurs on the basolateral surface of human
bronchial epithelial cells [59]. In comparison, IL-17RC as
recognized by the anti-ECD antibodies appeared to be
expressed by all cell types in the bronchial epithelium and
the underneath vascular endothelial cells (Figure 8,E'). It
is not clear what the role is for IL-17RC in these tissues.
Skin and lymphatic tissues
The squamous epithelium in the skin were not stained by
the anti-ICD antibodies but stained intermediately by the
anti-ECD antibodies (Figure 9,A and 9,A'). In the subepi-
dermis, the glandular cells (of either the sebaceous or
sweat glands) were stained weakly and strongly by the
anti-ICD and anti-ECD antibodies, respectively (Figure
9,B and 9,B'). The lymphatic cells in the lymph node,
spleen, thymus and tonsil were not stained by either anti-
bodies, although the lymphatic sinusoid or vascular
endothelium was stained positively by both antibodies
(Figure 9,C/C',D/D',E/E', and 9F/F'). This observation is
consistent to the previous report that IL-17RC mRNA lev-
els were very low in the thymus and spleen [35].
Miscellaneous tissues
The skeletal muscle cells were not stained by the anti-ICD
antibodies but stained weakly by the anti-ECD antibodies,
although the vascular endothelium was stained strongly
by both antibodies (Figure 10,A and 10,A'). The smooth
muscle cells of the intestine and uterus were not stained
by either antibodies (Figure 10,B/B' and 10C/C'). How-
ever, the vascular endothelium in uterus was stained
strongly by both antibodies (Figure 10,C/C'). The adi-
pocytes from the breast tissue were stained weakly by both
antibodies (Figure 10,D and 10,D'). In articular cartilage,
the chondrocytes were stained weakly by the anti-ICD
antibodies but not stained by the anti-ECD antibodies
(Figure 10,E and 10,E'). Similarly, the synovial lining cells
in the joint were stained intermediately by the anti-ICD
antibodies but not stained by the anti-ECD antibodies
(Figure 10,F and 10,F'), even though the vascular
endothelium was stained strongly by both antibodies. It is
not known how IL-17RC contributes to the pathogenesis
of rheumatoid arthritis [21,22].
Previous studies have shown that IL-17RC gene encodes
different mRNA splice isoforms and different proteins
[35,39,45,46]. The present study systematically examined
the IL-17RC protein expression in 53 human tissues. The
results showed different IL-17RC proteins were expressed
differentially in different human tissues, based on the sig-
nals detected by two distinct antibodies. The anti-ECD
antibodies recognized several endogenous IL-17RC pro-
tein bands that were larger than the recombinant full-International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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IL-17RC expression in the nervous system Figure 6
IL-17RC expression in the nervous system. Arrows: endothelium (capillaries in A', D', and E'; and arterioles in B, B', C', 
and D); and open arrows: motor neurons (E and E') and autonomic ganglia & nerves (F and F'). Original magnification: × 400.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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IL-17RC expression in the liver, gallbladder, pancreas, and salivary gland Figure 7
IL-17RC expression in the liver, gallbladder, pancreas, and salivary gland. Arrows: endothelium; and open arrows: 
hepatocytes (A and A') and epithelium (B and B'). Original magnification: × 400.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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IL-17RC expression in the urinary and respiratory systems Figure 8
IL-17RC expression in the urinary and respiratory systems. Arrows: endothelium; and open arrows: epithelium (A, A', 
B, B', C, C', E, and E') and alveolar lining cells (D and D'). Original magnification: × 400.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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IL-17RC expression in the skin and lymphatic tissues Figure 9
IL-17RC expression in the skin and lymphatic tissues. Arrows: endothelium; and open arrows: squamous epithelium (A 
and A'), glandular epithelium (B and B'), and lymphocytes (E, E', F, and F'). Original magnification: × 400.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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IL-17RC expression in miscellaneous tissues Figure 10
IL-17RC expression in miscellaneous tissues. Arrows: endothelium; and open arrows: skeletal muscle cells (A and A'), 
smooth muscle cells (C and C'), adipocytes (D and D'), articular chondrocytes (E and E'), and synovial cells (F and F'). Original 
magnification: × 400.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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length IL-17RC in a Western blot analysis, leading to a
speculation that the anti-ECD antibodies recognized the
glycosylated IL-17RC protein [46]. This is likely due to the
fact that the immunogen used to generate the antibodies
was expressed in mammalian cells and thus probably gly-
cosylated. On the other hand, the anti-ICD antibodies
were generated by using the 14-amino acid peptide, which
possibly had higher affinity for non-glycosylated IL-17RC
protein. The true identity of the stained IL-17RC proteins
needs to be further investigated. Nevertheless, it is
unlikely that the two antibodies recognized some proteins
other than IL-17RC, because it has been shown that both
antibodies recognized the recombinant full-length IL-
17RC and had no cross-reactivity with IL-17RA or IL-17RB
– two homologues of IL-17RC [46].
It is known that IL-17RC shares about 20% homology to
other IL-17 receptor family members [2]. The tissue-spe-
cific expression of other IL-17 receptor family members
has been investigated mainly through Northern blot and/
or RT-PCR analysis of mRNA expression. For example, IL-
17RA has been shown to be ubiquitously expressed in
many cell lines and tissues [5,60]. Expression of IL-17RB
is most pronounced in fetal and adult liver, kidney, pan-
creas, testis, brain, colon, and small intestines, but is
absent in peripheral blood leukocytes and lymphoid
organs [7,8]. IL-17RD is also named Similar expression to
fgf genes (Sef), which has several isoforms that are differ-
entially expressed in different tissues. Human Sef-a tran-
script was highly expressed in both fetal and adult brain,
pituitary, tonsils, spleen, adenoids, fetal kidney, liver, tes-
tes, and ovary, and moderate levels were detected in pri-
mary aortic endothelial cells, human umbilical vein
endothelial cells, and adrenal medulla. Low levels of Sef-
a were observed in adrenal cortex, barely detected in pla-
centa, and absent in thyroid. In contrast, Sef-b transcript
was highly expressed in thyroid and testes and moderately
expressed in pituitary, fetal brain, and human umbilical
vein endothelial cells; the remaining tissues were either
negative or expressed at barely detectable levels [61].
Human IL-17RE has not been characterized, although
mouse IL-17RE mRNAs have been shown to be mainly
expressed in the lung, kidney, stomach, and testis, but not
in heart, liver, spleen, or brain [62]. It would be interest-
ing to compare the protein expression profiles of all IL-17
receptor family members in future studies.
Conclusion
By immunohistochemical staining, IL-17RC protein was
detected in most human tissues. The cell types that
expressed IL-17RC protein include the myocardial cells,
vascular and lymphatic endothelial cells, glandular cells
(of the adrenal, parathyroid, pituitary, thyroid, pancreas,
parotid salivary, and subepidermal glands), epithelial
cells (of the esophagus, stomach, intestine, anus, renal
tubule, breast, cervix, Fallopian tube, epididymis, seminal
vesicle, prostate, gallbladder, bronchus, lung, and skin),
oocytes in the ovary, Sertoli cells in the testis, motor neu-
rons in the spinal cord, autonomic ganglia in the intes-
tine, skeletal muscle cells, adipocytes, articular
chondrocytes, and synovial cells. In particular, IL-17RC
protein expression was very high in most vascular and
lymphatic endothelium and squamous epithelium. The
epithelial cells of the breast, cervix, Fallopian tube, kid-
ney, bladder and bronchus also expressed high levels of
IL-17RC, so did the glandular cells in the adrenal cortex,
parotid salivary and subepidermal glands. In contrast, IL-
17RC protein was not detectable in some cell types such
as the smooth muscle cells, fibroblasts, antral mucosa of
the stomach, mucosa of the colon, endometrium of the
uterus, neurons of the brain, hepatocytes, or lymphocytes.
Nevertheless, IL-17RC was expressed in the vascular
endothelium within the tissues where the IL-17RC-nega-
tive cells resided. It is unlikely that the negative staining
was due to a technical artifact (false negative), because all
tissue cores were mounted and simultaneously stained on
a single slide and the positive tissue cores or positive vas-
cular endothelium within the negative tissue cores served
as internal positive controls. Therefore, the lack of IL-
17RC expression in some of the tissues reflects the tissue-
specific pattern of gene expression, which implies that IL-
17RC has no functional role in these tissues or the partic-
ular cell types.
It is speculated that IL-17RC may play a role in almost all
human tissues. It is further envisioned that different IL-
17RC proteins may determine the distinct cellular
responses to the ligands, particularly in those cell types
that do not express the IL-17RC protein as recognized by
the anti-ICD antibodies (for example, the squamous epi-
thelium of the esophagus, anus, and skin; and the epithe-
lium of breast, cervix, Fallopian tube, prostate, and
bronchus) but do express high levels of the IL-17RC pro-
tein as recognized by the anti-ECD antibodies.
The ligands of IL-17RC have been identified as IL-17A and
IL-17F and the intracellular signaling pathway for IL-17RA
has been revealed [45,48]. The IL-17 cytokines have been
shown to require a heterodimer of IL-17RA and IL-17RC
for mediating their signals [42,47]. However, the signal-
ing pathway downstream to IL-17RC is still a mystery
[14]. Nevertheless, in those tissues wherein IL-17RC is
expressed, IL-17RC may participate in inflammatory and
immune responses that have been demonstrated in stud-
ies of IL-17A and IL-17F [14,57,63], although the direct
role of IL-17RC is yet to be determined. The present find-
ings of IL-17RC expression in most human tissues may
stimulate further investigation into this under-studied but
presumably important member of IL-17 receptor family.International Archives of Medicine 2008, 1:19 http://www.intarchmed.com/content/1/1/19
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Methods
Antibodies and Reagents
Rabbit anti-IL-17RC intracellular domain antibodies
(anti-ICD) that recognize an intracellular domain (DSY-
FHPPGTPAPGR) of IL-17RC protein were affinity-purified
[35,39,40,46]. Goat anti-IL-17RC extracellular domain
antibodies (anti-ECD) were generated using the extracel-
lular domain of human IL-17RC isoform #3 (exon 7 was
spliced out) as immunogen (Catalog Number AF2269,
R&D Systems Inc., Minneapolis, MN) [46,47]. Due to the
polyclonal nature, the epitopes recognized by the anti-
ECD antibodies were unknown, which might be any
exons from 1 to 16 except exon 7. VECTSTAIN elite ABC
Reagent and DAB Substrate Kit were from Vector Labora-
tories, Burlingame, CA. The human normal tissue micro-
array (TMA) slides (Version CHTN2002N1) were
provided by the Cooperative Human Tissue Network
(CHTN). All tissue cores were made from the formalin
fixed paraffin embedded human normal adult tissues,
except the parathyroid and lymphatics that were from the
benign parathyroid adenoma and lymphangioma, respec-
tively (Table 1). Each tissue type was represented by four
0.6-mm tissue cores with a thickness of 4-μm on each
slide. The tissue type and quality of TMA slides were
assured by the provider's pathologist. The human tissue
samples have been de-identified in such a way that only
the age and sex of each donor were available to the inves-
tigators.
Immunohistochemical staining
The TMA slides were deparaffinized and rehydrated. Anti-
gen retrieval was performed by high-temperature (micro-
wave) incubation in 0.01 mol/L of citric acid buffer (pH
6.0) for 3 times of 4 min each. The slides were cooled
down to room temperature in about 10 min in citric acid
buffer and then transferred to phosphate-buffered saline
(pH 7.4). Endogenous peroxidase was blocked in a solu-
tion of 3% hydrogen peroxide in methanol for 30 min.
The slides were incubated for 20 min in a humidified
chamber in 10% normal goat or rabbit serum (Vector Lab-
oratories) and then in primary antibody solution over-
night at 4°C. Positive and negative control slides were the
prostate tumor slides with or without IL-17RC expression
as determined previously [40,46] and were run with or
without primary antibodies. Primary antibodies were
used at 7.5 μg/ml for the anti-ICD antibodies and 0.25 μg/
ml for the anti-ECD antibodies. The VECTSTAIN elite ABC
Reagent and DAB Substrate Kit were used according to the
manufacturer's protocol [40,64,65]. The slides were coun-
terstained in Mayer's hematoxylin. The staining condi-
tions were optimized by using several test slides. Similar
results were obtained from two TMA slides for each pri-
mary antibody. The stained slides were assessed inde-
pendently by all authors and a consensus was reached. In
order to present relative levels of IL-17RC expression, the
intensity of IL-17RC staining for a particular cell type in
the tissues was graded in this way: - = no staining; + =
weak; ++ = intermediate; +++ = strong.
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